Publications by authors named "M H Hemmelder"
Background: In 2020, the coronavirus disease 2019 (COVID-19) pandemic caused disruptions in kidney replacement therapy (KRT) services worldwide. The aim of this study was to assess the effect of the COVID-19 pandemic in 2020 on the incidence of KRT, kidney transplantation activity, mortality and prevalence of KRT across Europe.
Methods: Patients receiving KRT were included from 17 countries providing data to the European Renal Association Registry.
Background: Patients undergoing dialysis have an impaired health-related quality of life (HRQOL). There are conflicting data from small series on whether patient-related factors such as educational level have an impact on experienced HRQOL. The aim of this study was to investigate the association between educational level and HRQOL in dialysis patients.
View Article and Find Full Text PDFBackground: The burden of post COVID-19 condition (PCC) is not well studied in patients with advanced kidney disease.
Methods: A large prospective cohort of SARS-CoV-2 vaccinated patients with chronic kidney disease stages G4-G5 (CKD G4/5), on dialysis, and kidney transplant recipients (KTR) were included. Antibody levels were determined after vaccination.
Article Synopsis
- Primary glomerular disease (PGD) is a leading factor in end-stage kidney disease (ESKD), prompting the need for kidney replacement therapy (KRT), with the study analyzing trends in KRT incidence and patient outcomes across Europe from 2000 to 2019.
- The study included data from nearly 70,000 patients, revealing an average incidence of 16.6 per million, with significant variations across countries, and identifying immunoglobulin A nephropathy (IgAN) and focal segmental glomerulosclerosis (FSGS) as the most common types.
- Findings showed that while overall incidence declined initially, it stabilized after 2013, and patient survival rates varied among PGD subgroups,
Background: Chronic kidney disease (CKD) is often detected late, leading to substantial health loss and high treatment costs. Screening the general population for albuminuria identifies individuals at high risk of kidney events and cardiovascular disease (CVD) who may benefit from early start of preventive interventions. Previous studies on the cost-effectiveness of albuminuria population screening were inconclusive, but were based on survey or cohort data rather than an implementation study, modelled screening as performed by general practitioners rather than home-based screening, and often included only benefits with respect to kidney events.
View Article and Find Full Text PDF